Yaqoob M, McClelland P, Patrick A W, Stevenson A, Mason H, Bell G M
Royal Liverpool Hospital, England, United Kingdom.
Kidney Int Suppl. 1994 Nov;47:S101-4.
Tubular damage is a recognized feature of both overt diabetic nephropathy and glomerulonephritis. However, the pattern and mechanism of tubular damage in the two clinical settings remain unclear. Two groups of patients with macroalbuminuria (albuminuria > 300 mg/day) were studied. Group 1 comprised 41 patients with biopsy proven primary glomerulonephritis and group 2 comprised 28 patients with clinical diabetic nephropathy due to insulin dependent diabetes mellitus. Serum creatinine, creatinine clearance, glomerular proteinuria (albuminuria and transferrinuria), markers of tubular damage such as urinary excretion of lysosomal enzyme (N-acetyl glucosaminidase), brush border enzymes (leucine aminopeptidase and gamma-glutamyl transferase) and retinol binding protein (tubular protein) were measured. Both groups were comparable in serum creatinine, creatinine clearance, glomerular proteinuria and excretion of N-acetyl-glucosaminidase. However, a significantly higher degree of tubular brush border enzymuria and a lower level of tubular proteinuria were seen in group 1 than in group 2. In group 1, albuminuria correlated to tubular enzymuria and tubular proteinuria. However, there was no correlation in diabetic patients between parameters of glomerular and tubular damage or dysfunction. The data presented suggested that the pattern of tubulopathy is different in patients with comparable degree of macroalbuminuria due to diabetic nephropathy and glomerulonephritis. Moreover, in diabetic nephropathy contrary to glomerulonephritis, markers of tubular damage are unrelated to glomerular proteinuria. This may suggest different mechanisms of tubular damage in the two clinical settings. We recommended that in all patients with proteinuria, particularly those with diabetic nephropathy, markers of renal tubular damage may be useful in monitoring the course of their disease.
肾小管损伤是显性糖尿病肾病和肾小球肾炎的一个公认特征。然而,这两种临床情况下肾小管损伤的模式和机制仍不清楚。对两组大量蛋白尿(蛋白尿>300mg/天)患者进行了研究。第1组包括41例经活检证实的原发性肾小球肾炎患者,第2组包括28例因胰岛素依赖型糖尿病导致的临床糖尿病肾病患者。测量了血清肌酐、肌酐清除率、肾小球蛋白尿(白蛋白尿和转铁蛋白尿)、肾小管损伤标志物,如溶酶体酶(N-乙酰氨基葡萄糖苷酶)的尿排泄、刷状缘酶(亮氨酸氨肽酶和γ-谷氨酰转移酶)和视黄醇结合蛋白(肾小管蛋白)。两组在血清肌酐、肌酐清除率、肾小球蛋白尿和N-乙酰氨基葡萄糖苷酶排泄方面具有可比性。然而,第1组的肾小管刷状缘酶尿程度明显高于第2组,而肾小管蛋白尿水平则低于第2组。在第1组中,白蛋白尿与肾小管酶尿和肾小管蛋白尿相关。然而,糖尿病患者肾小球和肾小管损伤或功能障碍参数之间没有相关性。所呈现的数据表明,在因糖尿病肾病和肾小球肾炎导致的大量蛋白尿程度相当的患者中,肾小管病变模式不同。此外,与肾小球肾炎相反,在糖尿病肾病中,肾小管损伤标志物与肾小球蛋白尿无关。这可能提示这两种临床情况下肾小管损伤的机制不同。我们建议,在所有蛋白尿患者中,尤其是糖尿病肾病患者,肾小管损伤标志物可能有助于监测其疾病进程。